IDEXX Laboratories, Inc. $IDXX Stock: First Citizens Bank & Trust Co. Reduces Stake

First Citizens Bank & Trust Co. trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 16.7% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 22,537 shares of the company’s stock after selling 4,522 shares during the quarter. First Citizens Bank & Trust Co.’s holdings in IDEXX Laboratories were worth $11,769,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Triad Wealth Partners LLC raised its stake in IDEXX Laboratories by 3.1% in the first quarter. Triad Wealth Partners LLC now owns 600 shares of the company’s stock worth $337,000 after buying an additional 18 shares in the last quarter. KCM Investment Advisors LLC lifted its holdings in IDEXX Laboratories by 5.3% during the fourth quarter. KCM Investment Advisors LLC now owns 377 shares of the company’s stock worth $255,000 after buying an additional 19 shares during the period. Arlington Trust Co LLC boosted its position in IDEXX Laboratories by 46.3% during the 2nd quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock valued at $32,000 after acquiring an additional 19 shares in the last quarter. Evolve Private Wealth LLC boosted its position in IDEXX Laboratories by 3.2% during the 1st quarter. Evolve Private Wealth LLC now owns 640 shares of the company’s stock valued at $360,000 after acquiring an additional 20 shares in the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC increased its holdings in shares of IDEXX Laboratories by 21.4% in the 1st quarter. Annis Gardner Whiting Capital Advisors LLC now owns 119 shares of the company’s stock valued at $67,000 after acquiring an additional 21 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting IDEXX Laboratories

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: KeyCorp projects earnings growth beyond fiscal 2026, estimating EPS of $16.58 for FY2027 and $18.74 for FY2028. Those forecasts imply continued earnings expansion for IDEXX’s veterinary diagnostics business. KeyBanc initiates coverage of IDEXX Laboratories at sector weight
• Neutral Sentiment: KeyCorp’s quarterly forecasts are $3.70 EPS for Q3 2026, $3.34 for Q4 2026, $3.93 for Q1 2027, $4.61 for Q2 2027, $4.22 for Q3 2027 and $3.81 for Q4 2027. The firm estimates FY2026 EPS at $14.77, close to the broader consensus of $14.81.
• Negative Sentiment: KeyCorp’s FY2026 EPS estimate of $14.77 is modestly below the $14.81 consensus, while its Sector Weight rating offers no clear catalyst for investors seeking an upgrade or stronger near-term outlook. IDEXX also trades at a relatively elevated valuation, with a reported price-to-earnings ratio above 36.

Insider Activity at IDEXX Laboratories

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the sale, the director owned 9,568 shares in the company, valued at approximately $5,090,941.44. This represents a 18.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.79% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on IDXX. Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. KeyCorp initiated coverage on IDEXX Laboratories in a research note on Monday. They set a “sector weight” rating for the company. UBS Group upped their price objective on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Citigroup raised their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Finally, Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Six analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $747.00.

IDEXX Laboratories Trading Down 0.7%

NASDAQ:IDXX opened at $520.31 on Wednesday. IDEXX Laboratories, Inc. has a 52 week low of $500.61 and a 52 week high of $769.98. The firm has a 50 day moving average of $536.72 and a 200 day moving average of $552.17. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $40.99 billion, a price-to-earnings ratio of 36.59, a PEG ratio of 2.80 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The business had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.20 billion. During the same period in the previous year, the company earned $3.50 earnings per share. The business’s revenue for the quarter was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX’s companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.